SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.76 |
| Enterprise Value ($M) | 2.76 |
| Book Value ($M) | 0.00 |
| Book Value / Share | 0.00 |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | 0.00 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lind Global Fund II LP | 4.90 | -42.26 | |
| 13G/A | Hafner Ronald | 8.10 | ||
| 13G | Armistice Capital, Llc | 9.99 | ||
| 13G/A | YA II PN, Ltd. | -100.00 | ||
| 13G/A | Grisard Felix | 2.80 | -96.69 | |
| 13G | Alpha Capital Anstalt | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,302 | 25,042 | 25.17 | |
| 859 | 20,475 | 4.20 | |
| 854 | 19,016 | 4.49 | |
| 938 | 56,198 | 1.67 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NATR – Nature's Sunshine Products, Inc. | NERV – Minerva Neurosciences, Inc. |
| NKTR – Nektar Therapeutics | NRSN – NeuroSense Therapeutics Ltd. |
| NRXP – NRx Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io